Evaluation of the efficacy and safety of anti-allergic ophthalmic solution for the treatment of allergic conjunctivitis.

Evaluation of the efficacy and safety of anti-allergic ophthalmic solution for the treatment of allergic conjunctivitis. - Evaluation of the efficacy and safety of anti-allergic ophthalmic solution for the treatment of allergic conjunctivitis.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013073

Enrollment

100

Registered

2014-02-05

Start date

2014-02-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic conjunctivitis

Interventions

Epinastine hydrochloride ophthalmic solution Olopatadine hydrochloride ophthalmic solution

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1: Patients whose both eyes are diagnosed as allergic conjunctivitis. 2: Patients who provided written informed consent for participating in this study.

Exclusion criteria

Exclusion criteria: 1: Patients given immunotherapy. 2: Patients with surgical history in the internal eye (including laser therapy) within 3 months prior to enrollment. 3: Patients with allergy to drugs (including fluorescein) to be used during the research. 4: Patients taking medicines which affects the efficacy of study drug (including steroid, anti-allergic drugs and immunosuppressive drugs) during the research (patients can use drugs except for steroid and immunosuppressive drugs unless amount of drug is changed during the research). 5: Pregnant women, women of child-bearing potential or lactating women.

Design outcomes

Primary

Measure	Time frame
1: Change in scores of subjective symptoms (JACQLQ) 2: Changes in scores of objective symptoms (JACQLQ)	—

Secondary

Measure	Time frame
1: Frequency in use of steroid eyedrops. 2: Patient diary of allergic symptoms. 3: Evaluation of the corneal safety.	—

Countries

Japan

Contacts

Public ContactTakanori Mizoguchi

Mizoguchi Eye Clinic Ophthalmology

t-mizo@siren.ocn.ne.jp0956-22-5681

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026